Phenobarbital shows no clear advantage over diazepam for alcohol withdrawal, large study finds
Alcohol withdrawal is a common and dangerous medical emergency. Although benzodiazepines remain the standard treatment for this condition, the use of the barbiturate phenobarbital has increased by more than 200% in the last decade with limited evidence to suggest that this practice is safe and effective.
A large-scale study has found that phenobarbital and diazepam, both commonly used in alcohol withdrawal treatment, do not demonstrate a clear advantage over one another. Benzodiazepines have long been the go-to treatment for alcohol withdrawal, but the use of phenobarbital has surged by over 200% in recent years, despite a lack of strong evidence supporting its safety and effectiveness.
In this groundbreaking research, scientists compared the two drugs head-to-head and discovered that outcomes were virtually identical. Published in JAMA Internal Medicine, the study analyzed data from over 24,000 patients across 754 U.S. hospitals, carefully accounting for various factors such as age, comorbidities, and overall health to ensure comparable groups.
The researchers observed that patients receiving phenobarbital were less likely to leave the hospital prematurely against medical advice, a potential indication of differences in patient experiences between the medications, though further investigation is needed to confirm this finding. The findings suggest that hospitals have two reliable and safe treatment options for alcohol withdrawal, and clinicians may not feel compelled to abruptly switch from diazepam to phenobarbital.
This retrospective analysis provides reassuring evidence that both drugs offer comparable benefits and risks, allowing healthcare providers and institutions to make informed decisions based on solid data.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
